Targeting PD-1 in cancer: Biological insights with a focus on breast cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Programmed cell death-1 (PD-1) and its ligands regulate adaptive immunity, preventing tissue damage.
• Tumor cells exploit the PD-1 pathway to evade immune surveillance, making it a therapeutic target.
• Current PD-1-targeted therapies show clinical efficacy in various cancers but benefit a limited patient subset.

Purpose of the Study:

• To review the biological principles of targeting PD-1 in breast cancer.
• To discuss the functional and clinical implications of PD-1 blockade in breast cancer treatment.
• To highlight ongoing research into predictive biomarkers and combination strategies.

Main Methods:

• Literature review of studies on PD-1 pathway in cancer immunology.
• Analysis of clinical trial data for PD-1 inhibitors in breast cancer.
• Examination of research on biomarkers and combination therapies.

Main Results:

• PD-1 pathway is crucial for tumor immune evasion.
• PD-1 inhibitors offer clinical benefits but with limitations in response rates.
• Genomic and immune features are under investigation as predictive biomarkers.
• Combination strategies show promise but require further optimization.

Conclusions:

• Targeting PD-1 is a key strategy in breast cancer immunotherapy.
• Identifying predictive biomarkers is essential for patient selection.
• Combination therapies may enhance clinical outcomes but need further validation.